These highlights do not include all the information needed to use Daytrana® safely and effectively

‡‡‡HIGHLIGHTS OF PRESCRIBING INFORMATION exacerbation of symptoms in patients with pre-existing psychiatric illness.Clinical evaluation for Bipolar Disorder is recommended prior to stimulantThese highlights do not include all the information needed to use use. Monitor for aggressive behavior. (5.2)Daytrana® safely and effectively. See full prescribing information for • Seizures: Stimulants may lower the convulsive threshold. Discontinue in theDaytrana. presence of seizures. (5.3)® • Long-Term Suppression of Growth: Monitor height and weight atDAYTRANA (methylphenidate transdermal system)appropriate intervals in pediatric patients. (5.4)Initial U.S. Approval: 2006• Visual Disturbance: Difficulties with accommodation and blurring of visionhave been reported with stimulant treatment. (5.5)WARNING: DRUG DEPENDENCESee full prescribing information for complete boxed warning • Contact Sensitization: Use of Daytrana may lead to contact sensitization.Treatment should be discontinued if contact sensitization is suspected.• Daytrana should be given cautiously to patients with a history of drug Erythema is commonly seen with use of Daytrana and is not by itselfdependence or alcoholism. Chronic abusive use can lead to marked an indication of sensitization. However, contact sensitization should betolerance and psychological dependence with varying degrees of suspected if erythema is accompanied by evidence of a more intense localabnormal behavior. reaction (edema, ...